Galway, Ireland – – September 13, 2026 -- Neurent Medical has secured a €25 million growth debt financing facility from Claret Capital Partners to accelerate commercial expansion of its NEUROMARK® System for chronic rhinitis treatment.
Debt facility follows €62.5 million Series C round completed earlier in 2026
The new €25 million facility builds on Neurent Medical's €62.5 million Series C financing round, which closed earlier this year. The combined capital reinforces the company's position in minimally invasive treatments for chronic inflammatory sinonasal diseases.
Funds target sales expansion and balance sheet strength with minimal shareholder dilution
Neurent Medical will direct the financing toward commercial expansion of NEUROMARK®, increased investment in sales and marketing, and strengthening its balance sheet. CEO Brian Shields said the facility offers financial flexibility to execute growth strategy while limiting dilution to existing shareholders.
Claret Capital deepens existing relationship with device maker
Daniel Mallon, Principal at Claret Capital Partners, cited Neurent Medical's progress in establishing NEUROMARK as a leading treatment option for chronic rhinitis as the basis for continued backing. Claret Capital, Europe's largest independent growth debt fund manager, has invested over €1.5 billion since 2013 across more than 210 companies in technology, life sciences and impact sectors.